In humans, immunohistochemistry (IHC) using BerEP4 (which detects EpCAM) is reported to be an effective marker of BCC [10] and IHC panels including BerEP4 and CD10 [11], BerBP4 and EMA [12] or BerBP4 and CD34 [13] can reliably be used as a confirmatory diagnosis of BCC from the afore-mentioned differential diagnoses when needed in cases where the histopathological features are not typical. Here, EPCAM is linked to skin basal cell carcinoma.